Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma

Andrea R. Di Sebastiano, Andrew Deweyert, Simon Benoit, Erin Iredale, Hu Xu, Cleusa De Oliveira, Eugene Wong, Susanne Schmid, Matthew O. Hebb*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Glioblastoma (GBM) is the leading cause of high fatality cancer arising within the adult brain. Electrotherapeutic approaches offer new promise for GBM treatment by exploiting innate vulnerabilities of cancer cells to low intensity electric fields. This report describes the preclinical outcomes of a novel electrotherapeutic strategy called Intratumoral Modulation Therapy (IMT) that uses an implanted stimulation system to deliver sustained, titratable, low intensity electric fields directly across GBM-affected brain regions. This pilot technology was applied to in vitro and animal models demonstrating significant and marked reduction in tumor cell viability and a cumulative impact of concurrent IMT and chemotherapy in GBM. No off target neurological effects were observed in treated subjects. Computational modeling predicted IMT field optimization as a means to further bolster treatment efficacy. This sentinel study provides new support for defining the potential of IMT strategies as part of a more effective multimodality treatment platform for GBM.

Original languageEnglish (US)
Article number7301
JournalScientific reports
Issue number1
StatePublished - Dec 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Preclinical outcomes of Intratumoral Modulation Therapy for glioblastoma'. Together they form a unique fingerprint.

Cite this